Ann: Investor Presentation, page-8

First 8 Last

Share
Profile

Follow
skippa

1,303 Posts.

25

06/05/19

11:28

Post #: 38425678
Share

Originally posted by jake0002: ↑

How are investors to be attracted to AJX, if they have never heard of it, or have no practical knowledge of the company or its products?

Face-to-face meetings with the decision makers of brokers and investment funds will place AJX and its business right in their laps.

These trips to Aus are a chance to tell the AJX story to potential investors.

That is the way to boost the SP.

A stronger SP is good for everyone, particularly to enable AJX to refinance its debt.

Whilst AJX does not, and has not yet provided hard numbers on these new business agreements, I imagine it is because they are not allowed to by the ASX, and by the new business partners. AJX will certainly have a budget in mind for internal purposes, they cannot provide that info via the ASX.
So we s/h will have to await the various upcoming Qtrlies.

What these presentations reinforce, is that AJX actually does now have a business, and that the groundwork has been done, and now we need to wait for the results of those commercial deals to flow thru to the bottom line.

These presentations will impress upon the potential investors, that AJX investment proposition has been materially de-risked, and that NOW is the time to put some money into AJX.

Expand

These presentations have been a dime a dozen with AJX and if anything have resulted in a negative effect on the share price. I just wish they would be ‘quiet achievers’ and when success finally lands, then boast about it! But yes, I agree that now is the time to buy AJX.

AJX Price at posting: 15.5¢ Sentiment: Buy Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

There are more pages in this discussion • 9 more messages in this thread...

First 8 Last

Add AJX (ASX) to my watchlist

(20min delay)
Last 1.3¢		Change 0.000(0.00%)		Mkt cap ! $20.46M

Open	High	Low	Value	Volume
1.4¢	1.4¢	1.3¢	$2.2K	157.6K

Buyers (Bids)

No.	Vol.	Price($)
1	42000	1.2¢

Sellers (Offers)

Price($)	Vol.	No.
1.5¢	906200	4

View Market Depth

No.	Vol.	Price($)
1	42000	0.012
3	4058332	0.010
5	2072715	0.009
3	1186222	0.008
2	240000	0.007

Price($)	Vol.	No.
0.015	906200	4
0.016	429958	1
0.017	321118	2
0.018	115942	2
0.019	12500	1

Last trade - 14.20pm 07/10/2024 (20 minute delay)

AJX (ASX) Chart

Ann: Investor Presentation, page-8

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Investor Presentation, page-8

Top Stories

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News